evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/geneAliases/8,gene/geneAliases/9,gene/geneAliases/10,gene/geneAliases/11,gene/geneAliases/12,gene/geneAliases/13,gene/geneAliases/14,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract
9804,GENE_BACKGROUND,,"FGFR1 encodes fibroblast growth factor receptor 1, a receptor tyrosine kinase that is important for mitogenesis and differentiation. FGFR1 is composed of three immunoglobulin-like extracellular domains, a transmembrane component and a cytosolic tyrosine kinase domain that acts via the MAPK pathway (PMID: 8622701). The protein rapidly dimerizes and ultimately internalizes to the nucleus after binding of fibroblast growth factor ligands, primarily FGF1 and FGF2. However, binding varies with tissue distribution and ligand availability (PMID: 16597617). FGFR1 is widely expressed in tissue, and is necessary for a variety of functions such as embryonic development, skeletogenesis, mitogenesis and differentiation. Congenital mutations are associated with physical malformations, mental retardation and neurologic deficits (PMID: 23812909). Amplifying or activating mutations in FGFR1 occur in varying frequency in multiple cancers including those of the lung, breast, prostate, head and neck and esophagus (PMID: 21160078, 20179196, 14614009, 16807070, 12147242). In metastatic renal cell carcinoma, FGF signaling has been hypothesized to mediate acquired treatment resistance with angiogenic escape from VEGF-directed therapies (PMID: 24387233). Currently, a number of small molecule inhibitors of the FGFR proteins are in use, with the major difference among them being their specificity to FGFR versus other receptor tyrosine kinases (RTKs) (PMID: PMID: 23696246, 24265351).",,2017-04-17,,2260,FGFR1,fibroblast growth factor receptor 1,True,ENST00000425967,NM_001174067.1,N-SAM,FLT2,ECCL,CEK,HBGFR,HRTFDS,BFGFR,FGFR-1,FLT-2,OGD,FGFBR,HH2,bFGF-R-1,CD331,KAL2,False,21160078,Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.,Science translational medicine,2017-12-15T20:10:00,2,62,62ra93,Weiss J et al,doi: 10.1126/scitranslmed.3001451,,0001-12-15,,16807070,Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).,Oral oncology,2018-01-01T20:07:00,43,True,1960-06-01,Freier K et al,,,0001-01-01,,24387233,Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.,Expert opinion on investigational drugs,2018-03-01T20:14:00,23,3,305-15,Sonpavde G et al,doi: 10.1517/13543784.2014.871259,,0001-03-01,,16597617,Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.,The Journal of biological chemistry,2018-06-09T20:06:00,281,23,15694-700,Zhang X et al,,,2018-06-09T07:00:00,,8622701,Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction.,Molecular and cellular biology,0001-03-01,16,3,977-89,Mohammadi M et al,,,0001-03-01,,14614009,Gene amplifications associated with the development of hormone-resistant prostate cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-11-01T20:03:00,9,14,5271-81,Edwards J et al,,,0001-11-01,,12147242,Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH.,Biochemical and biophysical research communications,2018-08-09T20:02:00,296,True,152-5,Ishizuka T et al,,,0001-08-09,,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,Annals of oncology : official journal of the European Society for Medical Oncology,2018-03-01T20:14:00,25,3,552-63,Dienstmann R et al,doi: 10.1093/annonc/mdt419,,0001-03-01,,20179196,FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.,Cancer research,2018-03-01T20:10:00,70,5,2085-94,Turner N et al,doi: 10.1158/0008-5472.CAN-09-3746,,0001-03-01,,23812909,"FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly.",Journal of medical genetics,2018-09-01T20:13:00,50,9,585-92,Simonis N et al,doi: 10.1136/jmedgenet-2013-101603,,0001-09-01,,23696246,FGF receptors: cancer biology and therapeutics.,Medicinal research reviews,2018-03-01T20:14:00,34,2,280-300,Katoh M et al,doi: 10.1002/med.21288,,2018-03-01T03:00:00,
9803,GENE_SUMMARY,,"FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.",,2017-04-17,,2260,FGFR1,fibroblast growth factor receptor 1,True,ENST00000425967,NM_001174067.1,N-SAM,FLT2,ECCL,CEK,HBGFR,HRTFDS,BFGFR,FGFR-1,FLT-2,OGD,FGFBR,HH2,bFGF-R-1,CD331,KAL2,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
